MediciNovaTSE:4875 -5.58%28 Pretax Margin % is -1,382.87% as of Mar. 2026. GuruFocus rates TSE:4875 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, MediciNova ranks worse than 83.6% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. MediciNova's Pre-Tax Income for the
three
months ended in Mar. 2026 was 円-410.35 Mil. MediciNova's Revenue for the
three
months ended in Mar. 2026 was 円29.67 Mil. Therefore, MediciNova's pretax margin for the quarter that ended in Mar. 2026 was -1,382.87%.
The historical rank and industry rank for MediciNova's Pretax Margin % or its related term are showing as below:
TSE:4875'
s Pretax Margin % Range Over the Past 10 Years
Min: -2924.88 Med: -856.8 Max: -250.92
Current: -1961.98
TSE:4875's Pretax Margin % is ranked worse than 83.6% of 945
companies
in the Biotechnology industry
Industry Median: -90.63
vs TSE:4875: -1961.98
MediciNova (TSE:4875) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
MediciNova Pretax Margin % Related Terms
MediciNova Pretax Margin % Historical Data
* Premium members only.
The historical data trend for MediciNova's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4875 vs ENTX, IMA, ACRV: Pretax Margin % Comparison
For the Biotechnology subindustry, MediciNova's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediciNova Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediciNova's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where MediciNova's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediciNova (TSE:4875) has a Pretax Margin % of -1,382.87% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on MediciNova and its competitors. According to the industry distribution chart, MediciNova ranks #790 out of 945 companies in the Biotechnology industry, placing it in the top 83.6%.
Is MediciNova's Pretax Margin % too high?
MediciNova's current Pretax Margin % is -1,382.87%. Based on the distribution chart, MediciNova ranks #790 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MediciNova has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Pretax Margin % compare to ENTX and IMA?
According to the Biotechnology industry distribution chart, MediciNova ranks #790 out of 945 companies for Pretax Margin %. This places MediciNova in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on MediciNova and its competitors. MediciNova's current Pretax Margin % is -1,382.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (TSE:4875) has a current Pretax Margin % of -1,382.87%. The current Pretax Margin % is -1,382.87%. MediciNova's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For MediciNova (TSE:4875), the current Pretax Margin % is -1,382.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
28GF Score
Get the complete analysis for TSE:4875
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4875 has been successfully added to your 
